Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Dermatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Dermatology Other
    Elastography Can Help Distinguish Between Cancerous and Benign Skin Growths: Presented at RSNA - (DGDispatch)
    Blood Flow Cytometry May Be Preferable Way to Diagnose, Analyse Mycosis Fungoides: Presented at ASCP - (DGDispatch)
    Converting to Sirolimus From Calcineurin Inhibitors Reduces Risk of Skin Cancer in Kidney Transplant Patients: Presented at Renal Week 2009 - (DGDispatch)
    Spinosad Better Than Permethrin for Pediculosis Capitis in Children: Presented at AAP - (DGDispatch)
    Topical Onychomycosis Treatment More Effective Than Oral Treatment : Presented at EADV - (DGDispatch)

    News archive

     Recent webcasts/CME - Dermatology Other
      Adverse Cutaneous Reactions Induced by TNF-[alpha] Antagonist Therapy
      Advancements in Enzymatic Debridement: Applying Clinical Science to Everyday Applications
      The Prevention and Treatment of Pressure Ulcers
      Contemporary Options for the Management of Scars
      Pediatric and Adolescent Sports-Related Injuries and Ailments

      Webcasts/CME archive

       Recent cases - Dermatology Other
        Something Fishy
        Russell Bodies in a Skin Biopsy: A Case Report
        Yellow Nail Syndrome
        Acquired Perforating Dermatosis: Association with Diabetes and Renal Failure
        Complete Remission of Severe Idiopathic Cold Urticaria on Interleukin-1 Receptor Antagonist (Anakinra)

        Cases archive
          




        my personal edition > dermatology other > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Itraconazole Antifungal Shows Hepatic Safety

        A DGReview of :"Hepatic Safety of Itraconazole"
        Journal of Cutaneous Medicine and Surgery

        07/05/2002
        By David Loshak


        Pulse therapy with the oral antifungal agent itraconazole for onychomycosis appears to be safe. In particular, it does not threaten liver damage, despite some reports of hepatitis.

        Researchers at the University of Nevada, Las Vegas, United States, the University of Toronto, Canada, and in France investigated the drug's safety because of the increasing use of newer oral antifungal agents to treat superficial fungal infections.

        The researchers noted that itraconazole was effective and well tolerated with mostly minor and reversible side-effects. The most common adverse events were gastrointestinal upset, headache, and transient skin reaction. However, there had been rare reports of hepatitis.

        To assess the hepatic safety of pulse and continuous itraconazole, the researchers analysed all itraconazole clinical trials sponsored by Janssen Research Foundation in the treatment of onychomycosis where there had been an assessment of laboratory safety. They also reviewed published literature to assess the hepatic safety of itraconazole in common practice.

        The data indicated that itraconazole pulse treatment was safe, The incidence of all code 4 abnormalities was below 2 percent.

        There were reports, in the literature, of symptomatic hepatitis with itraconazole continuous therapy but none of symptomatic hepatotoxicity with the pulse regimen.

        The researchers pointed out that in the itraconazole package insert, liver function tests were recommended for patients receiving continuous itraconazole for more than one month. There was no such monitoring requirement for the pulse regimen unless the patient had a history of underlying hepatic disease or if the liver function tests were abnormal at baseline or at any time when signs or symptoms suggested liver dysfunction.
        Journal of Cutaneous Medicine and Surgery 2002;DOI:10.1007 s10227-001-0048-3 "Hepatic Safety of Itraconazole"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send